DuPont 2005 Annual Report Download - page 36

Part II
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations–Continued
In September 2002, the U.S. Food & Drug Administration (FDA) approved Cozaar to reduce the rate of progression of
nephropathy (kidney disease) in Type 2 diabetic patients with hypertension and nephropathy (hereafter referred to as the
RENAAL study). Through 2005, approvals based on the RENAAL study have been granted in 53 countries, with further approvals
pending.
The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) results were reported and published in
March 2002 at the annual meeting of the American College of Cardiology. The study found that use of Cozaar significantly
reduced the combined risk of cardiovascular death, heart attack and stroke in patients with hypertension and left ventricular
hypertrophy (LVH) compared to the beta-blocker atenolol. In March 2003, the FDA approved Cozaar as the first and only
hypertensive medicine to reduce the risk of stroke in patients with hypertension and LVH. In total, 62 countries have granted
regulatory licenses to Cozaar based on the LIFE study. In 2005, the FDA approved Hyzaar to reduce the risk of stroke based
on the LIFE study.
The FDA granted a new indication for Hyzaar in 2004 for use in patients with severe hypertension. This fixed dose combina-
tion is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of
achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients. In 2005, Hyzaar
100-12.5 mg tablets were introduced offering a new treatment alternative for doctors with patients whose blood pressure is not
adequately controlled by Cozaar 100 mg alone.
Outlook DuPont and Merck continue to support Cozaar and Hyzaar with clinical studies designed to identify additional
therapeutic benefits for patients with hypertension and co-morbid conditions. The company expects the ongoing Cozaar/
Hyzaar collaboration to continue to be an important contributor to earnings until the U.S. patents expire in 2010. Thereafter,
earnings are expected to decline significantly.
Segment
Sales PTOI
(Dollars in billions) (Dollars in millions)
2005 $5.2 $980
2004 4.7 837
2003 4.1 805
Safety & Protection satisfies the growing global needs of businesses, governments and consumers for solutions that make life
safer. By uniting market-driven science with the strength of highly-regarded brands such as Kevlar, Tyvek and Nomex,
Safety & Protection has built a unique presence in the marketplace since its inception in 2002.
The segment serves a large number of customers in markets that range from construction, transportation, communications,
industrial chemicals, oil, gas, and manufacturing to defense, homeland security, and safety consulting. In addition to serving its
existing customer base, the segment is investing in the future by going where the growth is. The segment’s growth initiatives
are a response to critical needs to help people feel safe at home and at work, to assist the government, military and law
enforcement and to preserve and protect the environment. These initiatives include building innovations, personal protection,
clean and disinfect, consumer safety, government solutions, environmental solutions, and safety consulting services. Addition-
ally, Safety & Protection works closely with businesses across the company, in areas like automotive safety and food safety, to
provide seamless access to products and technology.
36
SAFETY & PROTECTION